Vega Plus

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vega Plus

Quick Facts

Property Description
Active ingredient Sildenafil Citrate (INN: Sildenafil)
Form Oral Therapy (commonly film-coated tablet, oral suspension)
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use Conditions requiring enhanced localized blood flow
Origin Synthetic (chemically synthesized compound)

What is Vega Plus and its Active Substance?

Vega Plus is a prescription medicine defined by its sole active component, Sildenafil Citrate, which belongs to the Phosphodiesterase Type 5 (PDE5) inhibitor pharmacological class. This synthetic medicine was the first PDE5 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treating certain conditions, establishing a foundational role in this therapeutic category. The core identity of the drug rests on the internationally recognized non-proprietary name, Sildenafil.

As a single-component product, it provides a highly selective pharmacological action derived from inhibiting the PDE5 enzyme, an approach that is extensively studied and clinically recognized for its systemic effects. The compound's chemical structure is formulated as the citrate salt of sildenafil for optimal chemical stability and reliable absorption, a design principle common to many oral therapies.


The Pharmaceutical Form and General Purpose

The medication is supplied for oral therapy, most commonly as a film-coated tablet, but is also available as an Oral Suspension and an Injectable Solution for various clinical requirements. This range of dosage forms underscores its broad utility in specialized patient populations.

The general purpose of the PDE5 inhibitor mechanism is to promote localized vasodilation, involving the relaxation and widening of specific blood vessels. By facilitating enhanced blood flow to the required tissues, the medicine supports physiological processes necessary for male sexual function and aids in mitigating high pressure within the blood vessels of the lungs. The compound is pharmacologically established to sustain this targeted circulatory effect, offering a predictable therapeutic outcome in circulation-dependent conditions.

Regulatory References

  1. NIH StatPearls Sildenafil Monograph

What side effects are possible with Vega Plus?

Possible Side Effects and Safety Information

The safety profile of Sildenafil Citrate is characterized by adverse reactions classified into frequency tiers and related to specific organ systems, as documented in official regulatory sources. The most frequently reported effects are generally linked to the drug's vasodilatory mechanism.

Frequency-Classified Adverse Reactions

Adverse reactions are organized by regulatory frequency. Very common effects, occurring in at least 1 in 10 patients, include headache and flushing. Effects classified as common (occurring in up to 1 in 10 patients) involve the Nervous System (dizziness), Eye Disorders (visual disturbances such as blurred or color vision), Gastrointestinal Disorders (dyspepsia and nausea), and Musculoskeletal pain.

Less frequently reported, uncommon effects may include vomiting, palpitations, and hypotension. Rare, but medically significant, adverse reactions include Priapism (prolonged erection), Non-arteritic anterior ischemic optic neuropathy (NAION), and sudden decrease or loss of hearing, all of which are explicitly documented in regulatory labeling.

Population-Specific Notes and Restrictions

The official label contains safety considerations for specific populations. The medicine's clearance is known to be reduced in older adults (aged ge 65) and in patients with severe renal or hepatic impairment, potentially leading to increased plasma concentrations. Furthermore, Sildenafil Citrate is subject to a strict safety constraint: its use is absolutely contraindicated with the concurrent use of any form of nitrate donors due to the high risk of severe, life-threatening hypotension.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Sildenafil (Vega Plus) states that overdose primarily results in an increased incidence and severity of adverse reactions observed at therapeutic doses. In studies, single doses up to 800, mg resulted in pronounced symptoms such as severe headache, flushing, dizziness, dyspepsia, and visual disturbances like changes in color vision.

Overdose creates a critical risk of exaggerated systemic effects, most notably severe hypotension (a marked drop in blood pressure) and syncope. Treatment management is strictly symptomatic and supportive, as regulatory agencies confirm that no specific antidote is known for Sildenafil overdose. Furthermore, because the active substance is highly bound to plasma proteins, renal dialysis is not expected to accelerate clearance.

Immediate Medical Attention

Condition Required Action (As Mandated by Regulators)
Suspected Overdose or Severe Symptoms Seek immediate medical attention or contact emergency services.
Prolonged Erection Immediate medical assistance must be sought if an erection (priapism) persists for longer than 4 hours to prevent permanent penile tissue damage and loss of potency.

Therapeutic Uses of Vega Plus

Vega Plus (Sildenafil) is commonly used to help manage specific symptom clusters and may assist with enhancing physiological capacity across two distinct domains where compromised circulation leads to symptoms that create noticeable physiological strain. The medication is applied in clinical settings that involve episodic or fluctuating manifestations, and may be part of symptomatic management.

The primary therapeutic applications include addressing Erectile Dysfunction (ED), which involves difficulty achieving or maintaining an erection, and providing supportive care for Pulmonary Arterial Hypertension (PAH), a condition marked by increased physiological stress in the lungs.

This medication is used for managing symptom clusters that interfere with daily functioning, generally providing supportive relief that helps maintain a sense of stability when symptoms interfere with routine activities. For patients with PAH, this application is relevant in conditions presenting with systemic or localized discomfort, such as reduced exercise tolerance and fatigue. This treatment assists with maintaining stability and contributes to easing the overall symptom load during periods of heightened symptoms.

“This supportive therapeutic approach is used to help patients cope more steadily with symptom fluctuations and may assist with maintaining functional stability for relevant therapeutic contexts.”


Quick Fact: Supportive Relief for Symptoms

Area of Use Symptom Relief Focus Relevant Clinical Contexts
Sexual Health Difficulty in achieving or maintaining an erection. Episodic use, applied when symptomatic support is needed.
Cardiovascular/PAH Reduced exercise capacity and fatigue. Chronic, continuous management during periods of heightened symptoms.

Regulatory References

  1. NIH clinical overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

The eligibility for Vega Plus (Sildenafil Citrate) is determined by regulatory agencies based on a patient's concurrent medications, existing health conditions, and age. The information below strictly follows official governmental labeling on population restrictions.

Classification Population Status Defined by Regulators
Absolute Contraindications Use is strictly prohibited for patients taking Organic Nitrates (in any form) or Riociguat due to the risk of severe hypotension [Source 1.1, 3.5]. The medicine is also contraindicated in patients with known hypersensitivity to Sildenafil, recent history of stroke or myocardial infarction, severe hepatic impairment (for the ED indication), or Hypotension (BP < 90/50 mmHg) [Source 1.2, 1.5, 3.3].
Age-Related Rules The medicine is approved for Adults for both its indications. Use in Adult men is specified for the ED indication [Source 1.2]. For the PAH indication, it is approved for Pediatric patients ge 1 year [Source 2.7]. However, the FDA has recommended against chronic pediatric use due to safety concerns at high doses [Source 1.4, 2.5].
Conditional Use / Caution Patients with conditions predisposing to Priapism (e.g., Sickle Cell Anemia), anatomical deformation of the penis, or specific eye conditions like a history of NAION require cautious use [Source 1.5]. Use in Pregnancy and Lactation is not established [Source 1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Vega Plus (Sildenafil) into distinct pharmacokinetic and pharmacodynamic categories, defining specific restrictions on co-administration. Sildenafil is predominantly cleared by the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Pharmacodynamic and Contraindicated Interactions

Classification Interacting Agents Official Restriction
Contraindicated Organic Nitrates, Nitric Oxide Donors, Riociguat Prohibited due to risk of severe, symptomatic hypotension.
Use with Caution Alpha-blockers (e.g., Doxazosin), Antihypertensives Additive vasodilatory effects may result in low blood pressure.

Pharmacokinetic and Exposure Interactions

CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole, Erythromycin) substantially increase Sildenafil's plasma exposure by reducing its clearance. The interaction with Ritonavir is highly significant, requiring a regulatory limit of a 25 mg maximum single dose within a 48-hour period. Conversely, CYP3A4 Inducers (e.g., Bosentan, St. John’s Wort) decrease Sildenafil exposure. High-fat meals officially delay the absorption rate of the medicine. Furthermore, reduced clearance in patients with severe hepatic or renal impairment may amplify the effects of these pharmacokinetic interactions, as noted in the official prescribing information.

Mechanism of Action

Targeted Inhibition of the PDE5 Enzyme and cGMP Accumulation

The core mechanism of Sildenafil Citrate involves the selective competitive inhibition of the Phosphodiesterase Type 5 (PDE5) enzyme, an enzyme responsible for hydrolyzing the second messenger cGMP. By blocking PDE5, cGMP is prevented from being broken down, leading to its accumulation within the smooth muscle cells of the blood vessels. This sustained elevation of cGMP directly causes the relaxation of vascular smooth muscle and a resultant reduction in local vascular resistance.

Mechanism Dependence on the Nitric Oxide (NO) Pathway

Sildenafil does not initiate vasodilation directly but rather modulates the endogenous signaling system by stabilizing cGMP. Its mechanism is strictly reliant on the endogenous release of Nitric Oxide (NO), which is the prerequisite signal for cGMP synthesis. The NO-dependency dictates that the mechanism is only functional when the physiological signal for vasodilation is active, which results in localized increases in tissue perfusion.

Dosage and Administration Information

How to Use Vega Plus: Administration Guidelines

Administration of the active ingredient, Sildenafil, is governed by the specific condition being addressed, necessitating two distinct usage patterns: episodic or chronic. The medicine is supplied for Oral administration as film-coated tablets or a reconstituted suspension, and as an Intravenous (IV) solution.


Official Dosing and Frequency

Indication Starting Oral Dose Dosing Frequency Maximum Dose (per period)
Erectile Dysfunction (ED) 50 mg (as needed) Maximum once per day 100 mg
Pulmonary Arterial Hypertension (PAH) 20 mg (three times daily) Three times daily (TID) 80 mg TID

For the ED indication, the tablets should be administered approximately 30 minutes to 4 hours prior to activity. The tablets may be taken with or without food, though a high-fat meal may delay the onset of action.

For the PAH indication, the oral doses must be separated by approximately 4 to 6 hours. The intravenous solution is reserved for patients on the oral regimen who are temporarily unable to take medication by mouth, administered at a 10 mg bolus TID.


Population-Specific Adjustments

A lower starting dose of 25 mg is typically considered for patients with severe renal impairment or severe hepatic impairment (e.g., cirrhosis) when treating ED. A similar 25 mg starting dose is also used for older adults. Furthermore, the maximum dose is restricted to 25 mg within 48 hours when co-administered with ritonavir. For the chronic PAH regimen, a missed dose should be taken as soon as remembered, but a double dose should not be used to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Vega Plus

This overview describes the research landscape for Vega Plus (Sildenafil Citrate) by summarizing the types of studies that have been conducted and the functional measurements they explored. This is not medical advice and does not state or promise any personal outcomes.


Research evidence for Erectile Dysfunction (ED)

Studies exploring conditions characterized by functional limitations, such as Erectile Dysfunction, have primarily utilized randomized controlled trials (RCTs) and systematic reviews. These studies evaluate patient groups receiving the medication versus groups receiving a non-active substitute (placebo) over short-term intervals.

Outcomes measured included measures related to achieving and maintaining an erection sufficient for sexual intercourse. Researchers tracked patient-reported outcomes to assess how individuals perceived changes in their function and overall satisfaction during the study period. Research examined measured outcomes across various subgroups, including men with ED associated with conditions like diabetes mellitus and hypertension.


Research evidence for Pulmonary Arterial Hypertension (PAH)

Research exploring Sildenafil in Pulmonary Arterial Hypertension (PAH), a condition involving physiological strain, includes pivotal randomized controlled trials. These studies monitored outcomes related to functional capacity, such as the 6-Minute Walk Distance (6MWD), and physiological strain outcomes, specifically examining pressure measurements within the pulmonary arteries (hemodynamic parameters).

Trials also examined effects in different age groups, including studies focused on the pediatric PAH population. Short-term trials reported differences in functional parameters and examined measurements of pulmonary pressures between the study groups.


Evidence Gaps and Research Uncertainty

Current research highlights several areas where knowledge is still developing. A key limitation is that many studies are short-term, meaning there is limited information for long-term outcomes and the durability of the measured response. Comparative evidence is lacking for direct comparisons of Sildenafil against all other available active treatments for both indications. Furthermore, results apply only to the specific populations studied, meaning research does not determine whether an individual will respond similarly to the group patterns described.

Frequently Asked Questions (FAQ)

Common questions about Vega Plus (FAQ)


Q: Is Vega Plus the same as other similar drug names? What is the difference?

A: Vega Plus contains the active substance Sildenafil Citrate, which is the internationally recognized non-proprietary name (generic name) for the compound. Official prescribing information notes that Sildenafil is available under multiple brand names globally, often depending on the country or the specific condition it is prescribed to treat.


Q: How quickly can I expect to notice anything after starting Vega Plus?

A: Official pharmacokinetic data indicates that the medicine's maximum concentration in the bloodstream is typically reached between 30 and 120 minutes after taking an oral dose on an empty stomach, with a median time of about one hour. This time frame represents when the highest concentration of the drug is measured in the bloodstream.


Q: Does Vega Plus stay in your system for a long time?

A: Regulatory documents describe the mean terminal half-life (t1/2) of the active ingredient, Sildenafil, as approximately four hours. The half-life refers to the time it takes for the concentration of the medication in the body to reduce by half.


Q: Are there any common foods or drinks that interact with Vega Plus?

A: Official safety information indicates that alcohol may potentiate the medicine's vasodilatory (blood vessel widening) effects, which could be associated with an increased risk of side effects like dizziness and headache. Some regulatory sources also note that grapefruit juice may increase the body's exposure to the drug. High-fat meals can delay its absorption.


Q: Can Vega Plus affect my sleep schedule?

A: Official drug labels for the treatment of Pulmonary Arterial Hypertension (PAH) list difficulty sleeping (insomnia) as a commonly reported adverse reaction in patients with this indication.


Q: Is Vega Plus considered a long-term medication?

A: The pattern of use depends on the condition being treated. The official documents describe the medicine as intended for episodic, as-needed use for Erectile Dysfunction (ED) but as a chronic, continuous regimen for Pulmonary Arterial Hypertension (PAH).


Q: Can Vega Plus interact with common over-the-counter pain relievers?

A: No clinically significant interaction has been established in official documents between Sildenafil and common over-the-counter pain relievers like acetaminophen or NSAIDs (e.g., ibuprofen). Regulatory bodies note the importance of discussing all medications, including over-the-counter products, with a healthcare professional.


Q: Is it possible to develop a dependency on Vega Plus?

A: Sildenafil is described in official sources as not physically addictive and is not associated with the development of physical dependence or chemical withdrawal symptoms. The medicine is not chemically associated with the development of physical dependence.


Q: Is there a generic version of Vega Plus available?

A: Yes, the active ingredient, Sildenafil Citrate, is widely available as a generic medication. The generic form became available in various markets following the expiration of the original brand-name product patents.


Q: Can I take Vega Plus if I also take a blood thinner?

A: The co-administration of Sildenafil and blood thinners (anticoagulants) may require caution and monitoring due to potential effects on coagulation. Studies have noted an increased incidence of nosebleeds in some patients on both medications.


Q: Is there a known effect of Vega Plus on driving or operating machinery?

A: Given the potential for side effects such as dizziness and visual disturbances (e.g., blurred or color vision), caution regarding activities like driving or operating machinery is noted in the official labeling.


Q: What is the maximum recommended duration for taking Vega Plus?

A: The duration of use is determined by the official indication. For Erectile Dysfunction, use is as needed (episodic). For Pulmonary Arterial Hypertension, it is a chronic regimen often used long-term, though research highlights limited data on long-term outcomes and the durability of response beyond the trial periods.


Q: Are there known interactions between Vega Plus and supplements like vitamins?

A: Regulatory guidance advises that it cannot be guaranteed that all herbal remedies and supplements, including common vitamins, are safe to take concurrently with Sildenafil. Regulatory guidance emphasizes the importance of informing a healthcare professional about all supplements being used.


Q: Why is the drug administered in the way it is (e.g., 'once a day')?

A: The specific dosing schedule, such as once daily or three times daily, is based on the drug's pharmacokinetic profile (how the body handles the drug) and the clinical requirement for treating the specific indication. For chronic conditions, dosing is adjusted to maintain a sustained therapeutic level.


Q: What is the difference between the immediate-release and extended-release versions of Vega Plus?

A: Official labeling indicates that the active ingredient is supplied in several forms, including a conventional film-coated tablet (often Immediate Release, or IR) and an Oral Suspension. These different formulations primarily affect the speed of administration and absorption, not the active component itself.


Q: What is the purpose of the black box warning on Vega Plus packaging (if applicable)?

A: The official labeling for the Pulmonary Arterial Hypertension (PAH) product includes a cautionary statement, often called a Boxed Warning, regarding chronic pediatric use at high doses. This warning was added following a long-term trial that raised concerns about mortality risk in this specific subgroup.


Q: Do the effects of Vega Plus build up over time in the body?

A: Pharmacokinetic information indicates that the drug has a relatively short half-life of approximately four hours. Therefore, Sildenafil is rapidly cleared from the body. The chronic use for PAH is designed to establish and maintain a therapeutic effect over time.


Q: Is Vega Plus commonly used in other countries besides the US?

A: Yes, Sildenafil is an internationally recognized compound and is approved for medical use by major regulatory agencies globally, including the European Medicines Agency (EMA) and the UK’s NHS, for its designated indications.


Q: Are there any known issues with fertility while using Vega Plus?

A: The medicine is not approved for use in fertility treatment. Official regulatory data primarily focuses on general reproductive toxicity and does not establish safety or efficacy in this context.


Q: Can I use Vega Plus if I am allergic to similar medications?

A: Official documents state that the medicine is strictly contraindicated (prohibited) in patients with a known hypersensitivity (severe allergy) to Sildenafil itself or to any of its inactive components. The label does not explicitly extend this contraindication to other medications within the same PDE5 inhibitor class.


Q: Why do some people experience [specific, common side effect] when starting Vega Plus?

A: These common side effects, such as headache and flushing, are generally understood to be related to the drug’s fundamental mechanism of action. By widening blood vessels (vasodilation) in the body, the drug can cause these common effects.


Q: What are the most common reasons people stop taking Vega Plus in studies?

A: Summaries of clinical trial data indicate that the most common reasons patients may stop using the medication are typically due to either insufficient response (lack of achieving the desired outcome) or the occurrence of adverse events (side effects).

How should Vega Plus be stored and disposed of?

How to Store and Dispose of Vega Plus?

The storage and disposal of this medication, which contains Sildenafil, must adhere strictly to official regulatory guidelines to maintain product integrity and ensure household safety.

Storage Requirements

Store the tablets at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in the original container, which must be tightly closed and stored in a dry place away from excess moisture or light. Do not freeze the medicine. All forms must be stored out of the reach and sight of children.

Disposal Instructions

Dispose of unused or expired Vega Plus through a formal drug take-back program. If this is not an option, mix the tablets with an undesirable substance (like dirt or coffee grounds), place the mixture in a sealed bag, and discard it in the household trash. Do not flush the medication down a toilet or pour it into drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vega Plus found in:

A-Z Index: